WO1995007931A1 - Acylated insulin - Google Patents

Acylated insulin Download PDF

Info

Publication number
WO1995007931A1
WO1995007931A1 PCT/DK1994/000347 DK9400347W WO9507931A1 WO 1995007931 A1 WO1995007931 A1 WO 1995007931A1 DK 9400347 W DK9400347 W DK 9400347W WO 9507931 A1 WO9507931 A1 WO 9507931A1
Authority
WO
WIPO (PCT)
Prior art keywords
human insulin
ala
glu
gln
gly
Prior art date
Application number
PCT/DK1994/000347
Other languages
English (en)
French (fr)
Inventor
Svend Havelund
John Broberg HALSTRØM
Ib Jonassen
Asser Sloth Andersen
Jan Markussen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26065125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1995007931(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DK104493A external-priority patent/DK104493D0/da
Priority to AT94926816T priority Critical patent/ATE204882T1/de
Priority to UA96030967A priority patent/UA45321C2/uk
Priority to DE69428134T priority patent/DE69428134T2/de
Priority to AU76520/94A priority patent/AU682061B2/en
Priority to NZ273285A priority patent/NZ273285A/en
Priority to SI9430396T priority patent/SI0792290T1/xx
Priority to DK94926816T priority patent/DK0792290T3/da
Priority to KR1019960701400A priority patent/KR100310122B1/ko
Priority to EP94926816A priority patent/EP0792290B1/en
Priority to BR9407508A priority patent/BR9407508A/pt
Priority to SK324-96A priority patent/SK282495B6/sk
Priority to RO96-00583A priority patent/RO112873B1/ro
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to DE122004000035C priority patent/DE122004000035I2/de
Priority to PL94313444A priority patent/PL178466B1/pl
Priority to CA002171424A priority patent/CA2171424C/en
Priority to HU9600676A priority patent/HU217684B/hu
Priority to JP7508923A priority patent/JP3014764B2/ja
Priority to US08/400,256 priority patent/US5750497A/en
Publication of WO1995007931A1 publication Critical patent/WO1995007931A1/en
Priority to BG100420A priority patent/BG61611B1/bg
Priority to NO19961070A priority patent/NO316944B1/no
Priority to FI961220A priority patent/FI117055B/fi
Priority to FR04C0020C priority patent/FR04C0020I2/fr
Priority to LU91101C priority patent/LU91101I2/xx
Priority to NL300160C priority patent/NL300160I2/nl
Priority to NO2004006C priority patent/NO2004006I1/no
Priority to US11/169,100 priority patent/US20060030518A1/en
Priority to NO2017041C priority patent/NO2017041I2/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to novel human insulin derivatives which are soluble and have a protracted profile of action, to a method of providing such derivatives, to pharmaceutical compositions containing them, and to the use of such insulin derivatives in the treatment of diabetes.
  • Many diabetic patients are treated with multiple daily insulin injections in a regimen comprising one or two daily injections of a protracted insulin to cover the basal requirement supplemented by bolus injections of a rapid acting insulin to cover the requirement related to meals.
  • Protracted insulin compositions are well known in the art.
  • one main type of protracted insulin compositions comprises injectable aqueous suspensions of insulin crystals or amorphous insulin.
  • the insulin compounds utilized typically are protamine insulin, zinc insulin or protamine zinc insulin.
  • Certain drawbacks are associated with the use of insulin suspensions.
  • the insulin particles must be suspended homogeneously by gentle shaking before a defined volume of the suspension is withdrawn from a vial or expelled from a cartridge.
  • the temperature must be kept within more narrow limits than for insulin solutions in order to avoid lump formation or coagulation.
  • protamines While it was earlier believed that protamines were non-immunogenic, it has now turned out that protamines can be immunogenic in man and that their use for medical purposes may lead to formation of antibodies (Samuel et al., Studies on the immunogenecity of protamines in humans and experimental animals by means of a micro-complement fixation test, Clin. Exp. Immunol. 33, PP. 252-260 (1978)).
  • protamine-insulin complex is itself immunogenic (Kurtz et al., Circulating IgG antibody to protamine in patients treated with protamine-insulins. Diabetologica 25, pp. 322-324 (1983)). Therefore, with some patients the use of protracted insulin compositions containing protamines must be avoided.
  • protracted insulin compositions are solutions having a pH value below physiological pH from which the insulin will precipitate because of the rise in the pH value when the solution is injected.
  • a drawback with these solutions is that the particle size distribution of the precipitate formed in the tissue on injection, and thus the timing of the medication, depends on the blood flow at the injection site and other parameters in a somewhat unpredictable manner.
  • a further drawback is that the solid particles of the insulin may act as a local irritant causing inflammation of the tissue at the site of injection.
  • WO 91/12817 discloses protracted, soluble insulin compositions comprising insulin complexes of cobalt (III). The protraction of these complexes is only intermediate and the bioavailability is reduced.
  • Human insulin has three primary amino groups: the N-terminal group of the A-chain and of the B-chain and the ⁇ -amino group of Lys B29 .
  • Several insulin derivatives which are substituted in one or more of these groups are known in the prior art.
  • US Patent No. 3,528,960 (Eli Lilly) relates to N-carboxyaroyl insulins in which one, two or three primary amino groups of the insulin molecule has a carboxyaroyl group. No specifically N ⁇ B29 -substituted insulins are disclosed.
  • JP laid-open patent application No. 1-254699 discloses insulin wherein a fatty acid is bound to the amino group of Phe B1 or to the ⁇ -amino group of Lys B29 or to both of these.
  • the stated purpose of the derivatisation is to obtain a pharmacologically acceptable, stable insulin preparation.
  • Insulins which in the B30 position have an amino acid having at least five carbon atoms which cannot necessarily be coded for by a triplet of nucleotides, are described in JP laid-open patent application No . 57-067548 (Shionogi) .
  • the insulin analogues are claimed to be useful in the treatment of diabetes mellitus, particularly in patients who are insulin resistant due to generation of bovine or swine insulin antibodies.
  • insulin derivative as used herein is meant a compound having a molecular structure similar to that of human insulin including the disulfide bridges between Cys A7 and Cys B7 and between Cys A20 and Cys B19 and an internal disulfide bridge between Cys A6 and Cys A11 , and which have insulin activity.
  • protracted injectable insulin compositions which are solutions and contain insulins which stay in solution after injection and possess minimal inflammatory and immunogenic properties.
  • One object of the present invention is to provide human insulin derivatives, with a protracted profile of action, which are soluble at physiological pH values.
  • Another object of the present invention is to provide a pharmaceutical composition comprising the human insulin derivatives according to the invention.
  • the present invention relates to an insulin derivative having the following sequence:
  • Xaa at positions A21 and B3 are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys;
  • Xaa at position B1 is Phe or is deleted
  • Xaa at position B30 is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms, in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the ⁇ -amino group of Lys 829 , (b) any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys, in which case the ⁇ -amino group of Lys B29 has a lipophilic substituent or (c) deleted, in which case the ⁇ -amino group of Lys 829 has a lipophilic substituent; and any Zn 2+ complexes thereof, provided that when Xaa at position B30 is Thr or Ala, Xaa at positions A21 and B3 are both Asn, and Xaa at position B1 is Phe, then the insulin derivative is a Zn 2+ complex.
  • the invention relates to a human insulin derivative in which the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; the A21 and the B3 amino acid residues are, independently, any amino acid residues which can be coded for by the genetic code except Lys, Arg and Cys; Phe B1 may be deleted; the ⁇ -amino group of Lys 829 has a lipophilic substituent which comprises at least 6 carbon atoms; and 2-4 Zn 2+ ions may be bound to each insulin hexamer with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and Phe B1 is not deleted, then 2-4 Zn 2+ ions are bound to each hexamer of the insulin derivative.
  • the invention relates to a human insulin derivative in which the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; the A21 and the B3 amino acid residues are, independently, any amino acid residues which can be coded for by the genetic code except Lys, Arg and Cys, with the proviso that if the B30 amino acid residue is Ala or Thr, then at least one of the residues A21 and B3 is different from Asn; Phe B1 may be deleted; and the ⁇ -amino group of Lys 829 has a lipophilic substituent which comprises at least 6 carbon atoms.
  • the invention relates to a human insulin derivative in which the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; the A21 and the B3 amino acid residues are, independently, any amino acid residues which can be coded for by the genetic code except Lys, Arg and Cys; Phe 81 may be deleted; the ⁇ -amino group of Lys 829 has a lipophilic substituent which comprises at least 6 carbon atoms; and 2-4 Zn 2+ ions are bound to each insulin hexamer.
  • the invention relates to a human insulin derivative in which the B30 amino acid residue is deleted. In another preferred embodiment, the invention relates to a human insulin derivative in which the B30 amino acid residue is Asp.
  • the invention relates to a human insulin derivative in which the B30 amino acid residue is Glu.
  • the invention relates to a human insulin derivative in which the B30 amino acid residue is Thr.
  • the invention relates to a human insulin derivative in which the B30 amino acid is a lipophilic amino acid having at least 10 carbon atoms. In another preferred embodiment, the invention relates to a human insulin derivative in which the B30 amino acid is a lipophilic ⁇ -amino acid having from 10 to 24 carbon atoms.
  • the invention relates to a human insulin derivative in which the B30 amino acid is a straight chain, saturated, aliphatic ⁇ -amino acid having from 10 to 24 carbon atoms.
  • the invention relates to a human insulin derivative in which the B30 amino acid is D- or L-N ⁇ -dodecanoyllysine.
  • the invention relates to a human insulin derivative in which the B30 amino acid is ⁇ -amino decanoic acid.
  • the invention relates to a human insulin derivative in which the B30 amino acid is ⁇ -amino undecanoic acid.
  • the invention relates to a human insulin derivative in which the B30 amino acid is ⁇ -amino dodecanoic acid. In another preferred embodiment, the invention relates to a human insulin derivative in which the B30 amino acid is ⁇ -amino tridecanoic acid.
  • the invention relates to a human insulin derivative in which the B30 amino acid is ⁇ -amino tetradecanoic acid.
  • the invention relates to a human insulin derivative in which the B30 amino acid is ⁇ -amino pentadecanoic acid. In another preferred embodiment, the invention relates to a human insulin derivative in which the B30 amino acid is ⁇ -amino hexadecanoic acid.
  • the invention relates to a human insulin derivative in which the B30 amino acid is an ⁇ -amino acid.
  • the invention relates to a human insulin derivative in which the A21 amino acid residue is Ala. In another preferred embodiment, the invention relates to a human insulin derivative in which the A21 amino acid residue is Gln.
  • the invention relates to a human insulin derivative in which the A21 amino acid residue is Gly.
  • the invention relates to a human insulin derivative in which the A21 amino acid residue is Ser.
  • the invention relates to a human insulin derivative in which the B3 amino acid residue is Asp.
  • the invention relates to a human insulin derivative in which the B3 amino acid residue is Gln. In another preferred embodiment, the invention relates to a human insulin derivative in which the B3 amino acid residue is Thr. In another preferred embodiment, the invention relates to a human insulin derivative in which the ⁇ -amino group of Lys B29 has a lipophilic substituent which is an acyl group corresponding to a carboxylic acid having at least 6 carbon atoms.
  • the invention relates to a human insulin derivative in which the ⁇ -amino group of Lys 829 has a lipophilic substituent which is an acyl group, branched or unbranched, which corresponds to a carboxylic acid having a chain of carbon atoms 8 to 24 atoms long.
  • the invention relates to a human insulin derivative in which the ⁇ -amino group of Lys 829 has a lipophilic substituent which is an acyl group corresponding to a fatty acid having at least 6 carbon atoms.
  • the invention relates to a human insulin derivative in which the ⁇ -amino group of Lys 829 has a lipophilic substituent which is an acyl group corresponding to a linear, saturated carboxylic acid having from 6 to 24 carbon atoms.
  • the invention relates to a human insulin derivative in which the ⁇ -amino group of Lys B29 has a lipophilic substituent which is an acyl group corresponding to a linear, saturated carboxylic acid having from 8 to 12 carbon atoms.
  • the invention relates to a human insulin derivative in which the ⁇ -amino group of Lys B29 has a lipophilic substituent which is an acyl group corresponding to a linear, saturated carboxylic acid having from 10 to 16 carbon atoms.
  • the invention relates to a human insulin derivative in which the ⁇ -amino group of Lys 829 has a lipophilic substituent which is an oligo oxyethylene group comprising up to 10, preferably up to 5, oxyethylene units.
  • the invention relates to a human insulin derivative in which the ⁇ -amino group of Lys 829 has a lipophilic substituent which is an oligo oxypropylene group comprising up to 10, preferably up to 5, oxypropylene units.
  • the invention relates to a human insulin derivative in which each insulin hexamer binds 2 Zn 2+ ions. In another preferred embodiment, the invention relates to a human insulin derivative in which each insulin hexamer binds 3 Zn 2+ ions.
  • the invention relates to a human insulin derivative in which each insulin hexamer binds 4 Zn 2+ ions.
  • the invention relates to the use of a human insulin derivative according to the invention for the preparation of a medicament for treating diabetes.
  • the invention relates to a pharmaceutical composition for the treatment of diabetes in a patient in need of such a treatment comprising a therapeutically effective amount of a human insulin derivative according to the invention together with a pharmaceutically acceptable carrier.
  • the invention relates to a pharmaceutical composition for the treatment of diabetes in a patient in need of such a treatment comprising a therapeutically effective amount of a human insulin derivative according to the invention, in mixture with an insulin or an insulin analogue which has a rapid onset of action, together with a pharmaceutically acceptable carrier.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a human insulin derivative according to the invention which is soluble at physiological pH values.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a human insulin derivative according to the invention which is soluble at pH values in the interval from about 6.5 to about 8.5.
  • the invention relates to a protracted pharmaceutical composition
  • a human insulin derivative according to the invention in another preferred embodiment, relates to a protracted pharmaceutical composition
  • a human insulin derivative according to the invention in another preferred embodiment, relates to a protracted pharmaceutical composition
  • a human insulin derivative according to the invention in another preferred embodiment, relates to a protracted pharmaceutical composition
  • a human insulin derivative according to the invention in another preferred embodiment, relates to a protracted pharmaceutical composition
  • the invention relates to a pharmaceutical composition which is a solution containing from about 120 nmol/ml to about 1200 nmol/ml, preferably about 600 nmol/ml of a human insulin derivative according to the invention.
  • the invention relates to a method of treating diabetes in a patient in need of such a treatment comprising administering to the patient a therapeutically effective amount of an insulin derivative according to this invention together with a pharmaceutically acceptable carrier.
  • the invention relates to a method of treating diabetes in a patient in need of such a treatment comprising administering to the patient a therapeutically effective amount of an insulin derivative according to this invention, in mixture with an insulin or an insulin analogue which has a rapid onset of action, together with a pharmaceutically acceptable carrier.
  • Examples of preferred human insulin derivatives according to the present invention in which no Zn 2+ ions are bound are the following:
  • N ⁇ B29 -tridecanoyl Ala A21 human insulin N ⁇ B29 -tetradecanoyl Ala A21 human insulin ,
  • N ⁇ B29 -dodecanoyl Gln B3 Glu B30 human insulin examples of preferred human insulin derivatives according to the present invention in which two Zn 2+ ions are bound per insulin hexamer are the following: (N ⁇ B29 -tridecanoyl des(B30) human insulin) 6 , 2Zn 2+ ,
  • Examples of preferred human insulin derivatives according to the present invention in which three Zn 2+ ions are bound per insulin hexamer are the following: (N ⁇ B29 -tridecanoyl des(B30) human insulin) 6 , 3Zn 2+ ,
  • Examples of preferred human insulin derivatives according to the present invention in which four Zn 2+ ions are bound per insulin hexamer are the following: (N ⁇ B29 -tridecanoyl des(B30) human insulin) 6 , 4Zn 2+ ,
  • Fig. 1 shows the construction of the plasmid pEA5.3.2
  • Fig. 2 shows the construction of the plasmid pEA108
  • Fig. 3 shows the construction of the plasmid pEA113.
  • A is adenine
  • C is cytosine
  • G is guanine
  • T is thymine
  • the insulin derivatives according to the present invention can be prepared i.a. as described in the following:
  • Insulin derivatives featuring in position B30 an amino acid residue which can be coded for by the genetic code, e.g. threonine (human insulin) or alanine (porcine insulin).
  • Human insulin is treated with a Boc-reagent (e.g. di-tert-butyl dicarbonate) to form (A1,B1)-diBoc human insulin, i.e., human insulin in which the N-terminal end of both chains are protected by a Boc-group.
  • a Boc-reagent e.g. di-tert-butyl dicarbonate
  • an acyl group is introduced in the ⁇ -amino group of Lys B29 by allowing the product to react with a N-hydroxysuccinimide ester of the formula X-OSu wherein X is the acyl group to be introduced.
  • TFA is used to remove the Boc-groups and the product, N ⁇ B29 -X human insulin, is isolated.
  • a single chain insulin precursor, extended in position B1 with an extension (Ext) which is connected to B1 via an arginine residue and in which the bridge from B30 to A1 is an arginine residue, i.e. a compound of the general formula Ext-Arg-B(1-30)-Arg-A(1-21), can be used as starting material.
  • Acylation of this starting material with a N-hydroxysuccinimide ester of the general formula X-OSu wherein X is an acyl group introduces the acyl group X in the ⁇ -amino group of Lys 829 and in the N-terminal amino group of the precursor.
  • Insulin derivatives with no amino acid residue in position B30 i.e. des(B30) insulins.
  • an acyl group is introduced in the ⁇ -amino group of Lys 829 by allowing the product to react with a N-hydroxysuccinimide ester of the formula X-OSu wherein X is the acyl group to be introduced.
  • TFA is used to remove the Boc-groups and the product, (N ⁇ B29 -X) des(B30) insulin, is isolated.
  • a single chain human insulin precursor which is extended in position B1 with an extension (Ext) which is connected to B1 via an arginine residue and which has a bridge from B30 to A1 can be a useful starting material.
  • the bridge is a peptide of the formula Y n -Arg, where Y is a codable amino acid except lysine and arginine, and n is zero or an integer between 1 and 35. When n>l, the Y's may designate different amino acids.
  • Preferred examples of the bridge from B30 to A1 are: AlaAlaArg, SerArg, SerAspAspAlaArg and Arg (European Patent No. 163529).
  • the degree of prolongation of the blood glucose lowering effect was studied in rabbits. Each insulin derivative was tested by subcutaneous injection of 12 nmol thereof in each of six rabbits in the single day retardation test. Blood sampling for glucose analysis was performed before injection and at 1, 2, 4 and 6 hours after injection. The glucose values found are expressed as percent of initial values.
  • the Index of Protraction which was calculated from the blood glucose values, is the scaled Index of Protraction (prolongation), see p. 211 in Markussen et al., Protein Engineering 1 (1987) 205-213. The formula has been scaled to render a value of 100 with bovine ultralente insulin and a value of 0 with Actrapid ® insulin (Novo Nordisk A/S, 2880 Bagsvaerd, Denmark).
  • T 50% is the time when 50% of the A14 Tyr( 125 I) analogue has disappeared from the site of injection as measured with an external ⁇ -counter (Ribel, U et al.. The Pig as a Model for Subcutaneous Absorption in Man. In: M. serrano-Rios and P.J. Lefebre (Eds) : Diabetes 1985; Proceedings of the 12th Congress of the International Diabetes Federation, Madrid, Spain, 1985 (Excerpta Medica, Amsterdam, (1986) 891-96).
  • Table 2 are given the T 50% values of a series of very protracted insulin analogues.
  • the analogues were administered in solutions containing 3 Zn 2+ per insulin hexamer.
  • the ⁇ -B29 amino group can be a component of an amide bond, a sulphonamide bond, a carbamide, a thiocarbamide, or a carbamate.
  • compositions containing a human insulin derivative according to the present invention may be administered parenterally to patients in need of such a treatment.
  • Parenteral administration may be performed by subcutaneous, intramuscular or intravenous injection by means of a syringe, optionally a pen-like syringe.
  • parenteral administration can be performed by means of an infusion pump.
  • a further option is a composition which may be a powder or a liquid for the administration of the human insulin derivative in the form of a nasal spray.
  • the injectable human insulin compositions of the invention can be prepared using the conventional techniques of the pharmaceutical industry which involves dissolving and mixing the ingredients as appropriate to give the desired end product.
  • the human insulin derivative is dissolved in an amount of water which is somewhat less than the final volume of the composition to be prepared.
  • An isotonic agent, a preservative and a buffer is added as required and the pH value of the solution is adjusted - if necessary - using an acid, e.g. hydrochloric acid, or a base, e.g. aqueous sodium hydroxide as needed.
  • the volume of the solution is adjusted with water to give the desired concentration of the ingredients.
  • isotonic agents are sodium chloride, mannitol and glycerol.
  • preservatives are phenol, m-cresol, methyl p-hydroxybenzoate and benzyl alcohol.
  • suitable buffers are sodium acetate and sodium phosphate.
  • a composition for nasal administration of an insulin derivative according to the present invention may, for example, be prepared as described in European Patent No. 272097 (to Novo Nordisk A/S).
  • the insulin compositions of this invention can be used in the treatment of diabetes.
  • the optimal dose level for any patient will depend on a variety of factors including the efficacy of the specific human insulin derivative employed, the age, body weight, physical activity, and diet of the patient, on a possible combination with other drugs, and on the severity of the case of diabetes. It is recommended that the daily dosage of the human insulin derivative of this invention be determined for each individual patient by those skilled in the art in a similar way as for known insulin compositions.
  • the human insulin derivatives of this invention may be used in mixture with other types of insulin, e.g. human insulin or porcine insulin or insulin analogues with a more rapid onset of action.
  • insulin analogues are described e.g. in the European patent applications having the publication Nos. EP 214826 (Novo Nordisk A/S), EP 375437 (Novo Nordisk A/S) and EP 383472 (Eli Lilly & Co.).
  • the present invention is further illustrated by the following examples which, however, are not to be construed as limiting the scope of protection.
  • the features disclosed in the foregoing description and in the following examples may, both separately and in any combination thereof, be material for realizing the invention in diverse forms thereof.
  • All expression plasmids are of the cPOT type. Such plasmids are described in EP patent application No. 171 142 and are characterized in containing the Schizosaccharomyces pombe triose phosphate isomerase gene (POT) for the purpose of plasmid selection and stabilization.
  • POT Schizosaccharomyces pombe triose phosphate isomerase gene
  • a plasmid containing the POT-gene is available from a deposited E. coli strain (ATCC 39685).
  • the plasmids furthermore contain the S. cerevisiae triose phosphate isomerase promoter and terminator (P TPI and T TPI ). They are identical to pMT742 (Egel-Mitani, M.
  • AGAGGTTTCTTCTACACTCCAAAGTCTGACGACGCT-3' (Asp B3 ) (SEQ ID NO: 3)
  • PCR Polymerase Chain Reaction
  • One cycle was performed: 94°C for 45 sec, 49°C for 1 min, 72°C for 2 min.
  • oligonucleotides #16 and #126 was added and 15 cycles were performed: 94°C for 45 sec, 45°C for 1 min,
  • the PCR mixture was loaded onto a 2.5 % agarose gel and subjected to electrophoresis using standard techniques (Sambrook et al., Molecular cloning. Cold Spring Harbour Laboratory Press, 1989).
  • the resulting DNA fragment was cut out of the agarose gel and isolated using the Gene Clean Kit (Bio 101 Inc., PO BOX 2284, La Jolla, CA 92038, USA) according to the manufacturer's instructions.
  • the purified PCR DNA fragment was dissolved in 10 ⁇ l of water and restriction endonuclease buffer and cut with the restriction endonucleases NcoI and Xba I according to standard techniques, run on a 2.5% agarose gel and purified using the Gene Clean Kit as described.
  • the plasmid pAK188 consists of a DNA sequence of 412 bp composed of a EcoRI/NcoI fragment encoding the synthetic yeast signal/leader gene LaC212spx3 (described in Example 3 of WO 89/02463) followed by a synthetic NcoI/XbaI fragment encoding the insulin precursor MI5, which has a SerAspAspAlaLys bridge connecting the B29 and the A1 amino acid residues (see SEQ ID NOS. 14, 15 and 16), inserted into the EcoRI/XbaI fragment of the vector (phagemid) pBLUESCRIPT IIsk(+/-) (Stratagene, USA).
  • the plasmid pAK188 is shown in Fig. 1.
  • the plasmid pAK188 was also cut with the restriction endonucleases NcoI and XbaI and the vector fragment of 3139 bp isolated.
  • the two DNA fragments were ligated together using T4 DNA ligase and standard conditions (Sambrook et al., Molecular Cloning, Cold Spring Harbour Laboratory Press, 1989).
  • the ligation mixture was transformed into a competent E. coli strain (R-, M+) followed by selection for ampicillin resistance. Plasmids were isolated from the resulting E. coli colonies using standard DNA miniprep technique (Sambrook et al., Molecular Cloning, Cold Spring Harbour Laboratory Press, 1989), checked with appropriate restrictions endonucleases i.e.
  • the selected plasmid was shown by DNA sequencing analyses (Sequenase, U.S. Biochemical Corp.) to contain the correct sequence for the Ala A21 , Asp B3 human insulin precursor and named pEA5.3.
  • the plasmid pKFN1627 is an E. coli - S. cerevisiae shuttle vector, identical to plasmid pKFN1003 described in EP patent No. 375718, except for a short DNA sequence upstream from the unique XbaI site.
  • this sequence is a 178 bp fragment encoding a synthetic aprotinin gene fused in-frame to the yeast mating factor alpha 1 signal-leader sequence.
  • the corresponding 184 bp sequence encodes the insulin precursor MI5 (Glu B1 , Glu B28 ) (i.e. B(l-29, Glu B1 ,Glu B28 )-SerAspAspAlaLys-A(1-21) fused in-frame to the mating factor alpha 1 sequence (see SEQ ID NOS. 17, 18 and 19).
  • the vector pKFN1627 is shown in Fig. 1.
  • pEA5.3 was cut with the restriction endonucleases EcoRI and XbaI and the resulting DNA fragment of 412 bp was isolated.
  • the yeast expression vector pKFN1627 was cut with the restriction endonucleases NcoI and XbaI and with NcoI and EcoRI and the DNA fragment of 9273 bp was isolated from the first digestion and the DNA fragment of 1644 bp was isolated from the second.
  • the 412 bp EcoRI/XbaI fragment was then ligated to the two other fragments, that is the 9273 bp NcoI I/XbaI fragment and the 1644 bp NcoI/EcoRI fragment using standard techniques.
  • the ligation mixture was transformed into E. coli as described above. Plasmid from the resulting E. coli was isolated using standard techniques, and checked with appropriate restriction endonucleases i.e. EcoRI, XbaI, NcoI, Hpa I. The selected plasmid was shown by DNA sequence analysis (using the Sequenase kit as described by the manufacturer, U.S. Biochemical) to contain the correct sequence for the Ala A21 Asp B3 human insulin precursor DNA and to be inserted after the DNA encoding the LaC212spx3 signal/leader DNA. The plasmid was named pEA5.3.2 and is shown in Fig. 1.
  • the DNA sequence encoding the LaC212spx3 signal/leader/Ala A21 Asp B3 human insulin precursor complex and the amino acid sequence thereof are SEQ ID NOS. 20, 21 and 22.
  • the plasmid pEA5.3.2 was transformed into S. cerevisiae strain MT663 as described in European patent application having the publication No. 214826 and the resulting strain was named yEA002.
  • the DNA encoding Ala A21 Thr B3 human insulin precursor was constructed in the same manner as described for the DNA encoding Ala A21 Asp B3 human insulin precursor in Example 1.
  • the DNA sequence encoding the LaC212spx3 signal/leader/Ala A21 Thr B3 human insulin precursor complex and the amino acid sequence thereof are SEQ ID NOS. 23, 24 and 25.
  • the plasmid pEA8.1.1 was shown to contain the desired sequence, transformed into S. cerevisiae strain MT663 as described in Example 1 and the resulting strain was named yEA005.
  • the DNA encoding Gly A21 Asp B3 human insulin precursor was constructed in the same manner as described for the DNA encoding Ala A21 Asp B3 human insulin precursor in Example 1.
  • the DNA sequence encoding the LaC212spx3 signal/leader/Gly A21 Asp B3 human insulin precursor complex and the amino acid sequence thereof are SEQ ID NOS. 26, 27 and 28.
  • the plasmid pEAl.5.6 was shown to contain the desired sequence, transformed into S. cerevisiae strain MT663 as described in Example 1 and the resulting strain was named yEA007.
  • the DNA encoding GlyA21 Thr B3 human insulin precursor was constructed in the same manner as described for the DNA encoding Ala A21 Asp B3 human insulin precursor in Example 1.
  • the DNA sequence encoding the LaC212spx3 signal/leader/Gly A21 Thr B3 human insulin precursor complex and the amino acid sequence thereof are SEQ ID NOS. 29, 30 and 31.
  • the plasmid pEA4.4.11 was shown to contain the desired DNA sequence, transformed into S. cerevisiae strain MT663 as described in Example 1 and the resulting strain was named yEA006.
  • oligonucleotides were synthesized: #220 5'-ACGTACGTTCTAGAGCCTGCGGGCTGC-3' (SEQ ID NO: 10) #263 5'-CACTTGGTTGAAGCTTTGTACTTGGTTTGTGGTGAAAGAGGTTTC
  • PCR Polymerase Chain Reaction
  • the following Polymerase Chain Reaction (PCR) was performed using the Gene Amp PCR reagent kit (Perkin Elmer, 761 Main Avewalk, CT 06859, USA) according to the manufacturer's instructions. In all cases, the PCR mixture was overlayed with 100 ⁇ l of mineral oil (Sigma Chemical Co, St. Louis, MO, USA).
  • the plasmid pAK220 (which is identical to pAK188) consists of a DNA sequence of 412 bp encoding the synthetic yeast signal/leader LaC212spx3 (described in Example 3 of WO 89/02463) followed by the insulin precursor MI5 (see SEQ ID NOS. 14, 15 and 16) inserted into the vector (phagemid) pBLUESCRIPT IIsk(+/-) (Stratagene, USA). 5 ⁇ l of oligonucleotide #220 (100 pmol)
  • PCR mixture was then loaded onto a 2% agarose gel and subjected to electrophoresis using standard techniques.
  • the resulting DNA fragment was cut out of the agarose gel and isolated using the
  • PCR DNA fragment was dissolved in 10 ⁇ l of water and restriction endonuclease buffer and cut with the restriction endonucleases HindIII and XbaI according to standard techniques.
  • the HindIII/XbaI DNA fragment was purified using The Gene Clean Kit as described.
  • the plasmid pAK406 consists of a DNA sequence of 520 bp comprising an EcoRI/HindIII fragment derived from pMT636 (described in WO 90/10075) encoding the yeast alpha factor leader and part of the insulin precursor ligated to the HindIII/XbaI fragment from pAK188 encoding the rest of the insulin precursor MI5 (see SEQ ID NOS. 32, 33 and 34) inserted into the vector cPOT.
  • the vector pAK406 is shown in Fig. 2.
  • the plasmid pAK233 consists of a DNA sequence of 412 bp encoding the synthetic yeast signal/leader LaC212spx3 (described in Example 3 of WO 89/02463) followed by the gene for the insulin precursor B(1-29)-GluLysArg-A(1-21) (A21-Gly) (see SEQ ID NOS. 35, 36 and 37) inserted into the vector cPOT.
  • the plasmid pAK233 is shown in Fig. 2.
  • the plasmid pAK233 was cut with the restriction endonucleases NcoI and XbaI and the vector fragment of 9273 bp isolated.
  • the plasmid pAK406 was cut with the restriction endonucleases NcoI and HindIII and the vector fragment of 2012 bp isolated. These two DNA fragments were ligated together with the HindIII/XbaI PCR fragment using T4 DNA ligase and standard conditions. The ligation mixture was then transformed into a competent E. coli strain (R-, M+) followed by selection for ampicillin resistance. Plasmids were isolated from the resulting E. coli colonies using a standard DNA miniprep technique and checked with appropriate restriction endonucleases i.e. EcoRI, XbaI, NcoI, HindIII.
  • the selected plasmid was shown by DNA sequencing analyses to contain the correct sequence for the Arg B31 single chain human insulin precursor DNA and to be inserted after the DNA encoding the S. cerevisiae alpha factor DNA.
  • the plasmid was named pEA108 and is shown in Fig. 2.
  • the DNA sequence encoding the alpha factor leader/Arg B31 single chain human insulin precursor complex and the amino acid sequence thereof are SEQ ID NOS. 38, 39 and 40.
  • the plasmid pEA 108 was transformed into S. cerevisiae strain MT663 as described in Example 1 and the resulting strain was named yEA108.
  • PCR Polymerase Chain Reaction
  • the plasmid pAK401 consists of a DNA sequence of 523 bp composed of an EcoRI/NcoI fragment derived from pMT636 (described in WO 90/10075) (constructed by by introducing a NcoI site in the 3'-end of the alpha leader by site directed mutagenesis) encoding the alpha factor leader followed by a NcoI/XbaI fragment from pAK188 encoding the insulin precursor MI5 (see SEQ ID NOS. 41, 42 and 43) inserted into the vector (phagemid) pBLUESCRIPT IIsk(+/-) (Stratagene, USA).
  • the plasmid pAK401 is shown in Fig. 3.
  • the plasmid pAK401 was cut with the restriction endonucleases NcoI and XbaI and the vector fragment of 3254 bp isolated and ligated together with the NcoI/XbaI PCR fragment.
  • the ligation mixture was then transformed into a competent E. coli strain and plasmids were isolated from the resulting E. coli colonies using a standard DNA miniprep technique and checked with appropriate restriction endonucleases i.e. EcoRI, XbaI, NcoI.
  • the selected plasmid, named pll3A (shown in Fig. 3), was cut with EcoRI and XbaI and the fragment of 535 bp isolated.
  • the plasmid pAK233 was cut with the restriction endonucleases NcoI and XbaI, and with EcoRI/NcoI and the fragments of 9273 and 1644 bp isolated. These two DNA fragments were ligated together with the EcoRI/XbaI fragment from pll3A using T4 DNA ligase and standard conditions. The ligation mixture was then transformed into a competent E. coli strain (R-, M+) followed by selection for ampicillin resistance. Plasmids were isolated from the resulting E. coli colonies using a standard DNA miniprep technique and checked with appropriate restriction endonucleases i.e. EcoRI, XbaI, NcoI, HindIII.
  • the selected plasmid was shown by DNA sequencing analyses to contain the correct sequence for the Arg B31 single chain human insulin precursor DNA with the N-terminal extension GluGluAlaGluAlaGluAlaArg and to be inserted after the DNA encoding the S. cerevisiae alpha factor DNA.
  • the plasmid was named pEA113 and is shown in Fig. 3.
  • the DNA sequence encoding the alpha factor leader/Arg B-1 Arg B31 single chain human insulin precursor having an N-terminal extension (GluGluAlaGluAlaGluAlaArg) and the amino acid sequence thereof are SEQ ID NOS. 44, 45 and 46.
  • the plasmid pEA113 was transformed into S. cerevisiae strain MT663 as described in Example 1 and the resulting strain was named yEA113.
  • GluGluAlaGluAlaGluAlaGluArg was constructed in the same manner as described for the DNA encoding alpha factor leader/Arg B-1 Arg B31 single chain human insulin precursor having an N-terminal extension (GluGluAlaGluAlaGluAlaArg) in Example 5.
  • the plasmid was named pEA136.
  • the DNA sequence encoding the alpha factor leader/Arg B-1 Arg B31 single chain human insulin precursor having an N-terminal extension (GluGluAlaGluAlaGluAlaGluArg) and the amino acid sequence thereof are SEQ ID NOS. 47, 48 and 49.
  • the plasmid pEA136 was transformed into S. cerevisiae strain MT663 as described in Example 1 and the resulting strain was named yEA136.
  • (A1,B1)-diBoc insulin was purified by reversed phase HPLC as follows: The crude product was dissolved in 100 ml of 25% ethanol in water, adjusted to pH 3.0 with HCl and applied to a column (5 cm diameter, 30 cm high) packed with octadecyldimethylsilyl-substituted silica particles (mean particle size 15 ⁇ m, pore size 100 A) and equilibrated with elution buffer. The elution was performed using mixtures of ethanol and 1 mM aqueous HCl, 0.3 M KCl at a flow of 2 1/h. The insulin was eluted by increasing the ethanol content from 30% to 45%.
  • Boc protecting groups were eliminated by addition of 4 ml of TFA.
  • the dissolved material was incubated for 30 minutes and then precipitated by addition of 50 ml of acetone.
  • the precipitate was isolated by centrifugation and dried in vacuum.
  • N ⁇ B29 -benzoyl human insulin was purified by reversed phase HPLC as described in Example 7. A yield of 230 mg was obtained. Recrystallization from 15% aqueous ethanol containing 6 mM Zn 2+ and 50 mM citrate at pH 5.5 gave crystals of the title compound which were isolated by centrifugation and dried in vacuum. The yield was 190 mg.
  • the Boc protecting groups were eliminated by addition of 4 ml of TFA.
  • the dissolved material was incubated for 30 minutes and then precipitated by addition of 50 ml of acetone.
  • the precipitate was isolated by centrifugation and dried in vacuum. The yield was 376 mg.
  • B29-lithocholoyl insulin was purified by reversed phase HPLC as described in Example 7. A final yield of 67 mg was obtained at a purity of 94%. Recrystallization from 15% aqueous ethanol containing 6 mM Zn 2+ and 50 mM citrate at pH 5.5 gave crystals of the title compound which were isolated by centrifugation and dried in vacuum. The yield was 49 mg.
  • the Boc protecting groups were eliminated by addition of 4 ml of TFA.
  • the dissolved material was incubated for 30 minutes and the product was then precipitated by addition of 50 ml of acetone.
  • the precipitate was isolated by centrifugation and dried in vacuum. The yield of crude product was 420 mg.
  • bovine carboxypeptidase A 50 mg was suspended in 25 ml of water and isolated by centrifugation. The crystals were suspended in 25 ml of water and 1 M ammonia was added until a clear solution was obtained at a final pH of 10. The carboxypeptidase solution was added to the insulin solution and the reaction was allowed to proceed for 24 hours. A few drops of toluene were added to act as preservative during the reaction.
  • the des(B30) human insulin was crystallized by successive addition of 80 g of sodium chloride while the solution was stirred. The pH value was then adjusted to 8.3 and the crystallization was allowed to proceed for 20 hours with gentle stirring. The crystals were isolated on a 1.2 ⁇ m filter, washed with 250 ml of ice cold 2-propanol and finally dried in vacuum.
  • the title compound was synthesized by a method similar to that described in Example 7, using des(B30) porcine insulin as the starting material.
  • the crude product was precipitated by acetone and dried in vacuum.
  • the (A1,B1)-diBoc des(B30) human insulin was purified by reversed phase HPLC as described in Example 7.
  • Porcine trypsin was immobilized to MiniLeak ® Low to a degree of substitution of 1 mg per ml of gel, using the conditions described above for immobilization of A. lyticus.
  • c Synthesis of Glu(GluAla) 3 Arg-B(1-29), ThrArg-A(1-21) insulin using immobilized A. lyticus protease
  • the product from the previous step, d., contained in approximately 2,65 ml of DMSO/DMF/N,N-diisopropylethylamine was diluted with 10.6 ml of a 50 mM glycine buffer comprising 20% ethanol and the pH adjusted to 10 with NaOH. After standing for 1 hour at room temperature 1 ml of MiniLeak gel, carrying 1 mg of immobilized trypsin per ml of gel, was added. The reaction mixture was stirred gently for 48 hours at room temperature.
  • reaction mixture was applied to a reversed phase HPLC column (5 cm in diameter, 30 cm high), packed with octadecyldimethylsilyl-substituted silica particles (mean particle size 15 ⁇ m, pore size 100 A).
  • octadecyldimethylsilyl-substituted silica particles mean particle size 15 ⁇ m, pore size 100 A.
  • 20 mM Tris/HCl buffers adjusted to pH 7.7 and comprising an increasing concentration of ethanol, from 40% to 44% (v/v), at a rate of 2000 ml/h.
  • the major peak eluting at about 43-44% of ethanol contained the title compound.
  • the fractions containing the major peak were pooled, water was added to reduce the ethanol concentration to 20% (v/v), and the pH was adjusted to 5.5.
  • the dried reaction mixture was dissolved in 25 ml of TFA, and the solution was left for 30 min at room temperature.
  • the TFA was removed by evaporation in vacuo.
  • the gelatinous residue was dissolved in 60 ml of water and the pH was adjusted to 11.2 using concentrated ammonia.
  • the title compound was crystallized from this solution by adjustment of the pH to 8.5 using 6 N HCl.
  • the product was isolated by centrifugation, washed once by 10 ml of water, and dried in vacuo. Yield 356 mg. Purity by HPLC 94%.
  • the product of this example is thus human insulin wherein the ⁇ -amino group of Lys B29 has a substituent of the following structure: CH 3 (CH 2 ) 12 CONHCH(CH 2 CH 2 COOH)CO-.
  • the title compound was synthesized analogously to N ⁇ B29 -dodecanoyl des(B30) human insulin as described in Example 14, by using undecanoic acid N-hydroxysuccinimide ester instead of dodecanoic acid N-hydroxysuccinimide ester.
  • the title compound was synthesized analogously to N ⁇ B29 -dodecanoyl des(B30) human insulin as described in Example 14, by using tridecanoic acid N-hydroxysuccinimide ester instead of dodecanoic acid N-hydroxysuccinimide ester.
  • the title compound was synthesized analogously to N ⁇ B29 -dodecanoyl des(B30) human insulin as described in Example 14, by using myristic acid N-hydroxysuccinimide ester instead of dodecanoic acid N-hydroxysuccinimide ester.
  • the title compound was synthesized analogously to N ⁇ B29 -dodecanoyl des(B30) human insulin as described in Example 14, by using palmitic acid N-hydroxysuccinimide ester instead of dodecanoic acid N-hydroxysuccinimide ester.
  • Disuccinimidyl suberate (1.0 g, Pierce) was dissolved in DMF (50 ml), and D-thyroxine (2.0 g, Aldrich) was added with stirring at 20°C. The thyroxine slowly dissolved, and after 20 hours the solvent was removed by evaporation in vacuo. The oily residue was crystallized from 2-propanol to yield 0.6 g of N- (succinimidylsuberoyl)-D-thyroxine, m.p. 128-133 °C. b. Reaction of (A1,B1)-diBoc human insulin with N-(succinimidylsuberoyl)-D-thyroxine.
  • the product of this example is thus human insulin wherein the ⁇ -amino group of Lys 829 has a substituent of the following structure: Thyrox-CO(CH 2 ) 6 CO-, wherein Thyrox is thyroxine which is bound to the octanedioic acid moiety via an amide bond to its ⁇ -amino group.
  • N-succinoyl- ⁇ -aminomyristic acid methyl ester (0.8 g) was dissolved in dry DMF (10 ml, Merck, dried over 4A molecular sieve). Dry pyridine (80 ⁇ l, Merck), and di(N-succinimidyl)carbonate (1.8 g, Fluka) were added, and the reaction mixture was stirred overnight at room temperature. The evaporation residue was purified by flash chromatography on silica gel 60 (Merck), and recrystallized from 2-propanol/petroleum ether (1/1). Yield of N-(succinimidylsuccinoyl)- ⁇ -aminomyristic acid methyl ester: 0.13 g, m.p. 64-66°C. d. Reaction of (A1,B1)-diBoc human insulin with N- (succinimidylsuccinoyl)- ⁇ -aminomyristic acid methyl ester.
  • the product of this example is thus human insulin wherein the ⁇ -amino group of Lys 829 has a substituent of the following structure: CH 3 (CH 2 ) 11 CH(COOH)NHCOCH 2 CH 2 CO-.
  • N ⁇ B29 -octyloxycarbonyl human insulin was 86 mg.
  • the product of this example is thus human insulin wherein the ⁇ -amino group of Lys B29 has a substituent of the following structure: CH 3 (CH 2 ) 7 OCO-.
  • This compound was prepared as described in Example 21 a.-c, using ⁇ -amino palmitic acid instead of ⁇ -amino myristic acid.
  • Example 21 d The reaction was carried out as in Example 21 d., but using N-(succinimidylsuccinoyl)- ⁇ -aminopalmitic acid methyl ester instead of N-(succinimidylsuccinoyl)- ⁇ -aminopalmitic acid methyl ester to give N ⁇ B29 -(2-succinylamido)palmitic acid human insulin.
  • the product of this example is thus human insulin wherein the ⁇ -amino group of Lys B29 has a substituent of the following structure: CH 3 (CH 2 ) 13 CH(COOH)NHCOCH 2 CH 2 CO-.
  • the product of this example is thus human insulin wherein the ⁇ -amino group of Lys B29 has a substituent of the following Structure: CH 3 (CH 2 ) 13 CH(COOH)NHCH 2 CH 2 OCOCH 2 CH 2 CO-.
  • the product of this example is thus des(B30) human insulin wherein the ⁇ -amino group of Lys 829 has a substituent of the following structure: lithocholoyl-NHCH(CH 2 CH 2 COOH)CO-.
  • a pharmaceutical composition comprising 600 nmol/ml of N ⁇ B29 -decanoyl des(B30) human insulin, 1/3Zn 2+ in solution.
  • N ⁇ B29 -decanoyl des(B30) human insulin (1.2 ⁇ mol) was dissolved in water (0.8 ml) and the pH value was adjusted to 7.5 by addition of 0.2 M sodium hydroxide. 0.01 M zinc acetate (60 ⁇ l) and a solution containing 0.75% of phenol and 4% of glycerol (0.8 ml) was added. The pH value of the solution was adjusted to 7.5 using 0.2 M sodium hydroxide and the volume of the solution was adjusted to 2 ml with water.
  • a pharmaceutical composition comprising 600 nmol/ml of N ⁇ B29 -decanoyl human insulin, 1 ⁇ 2Zn 2+ in solution.
  • the resulting solution was sterilized by filtration and transferred aseptically to a cartridge or a vial.
  • a pharmaceutical composition comprising 600 nmol/ml of N ⁇ B29 -lithocholoyl human insulin in solution.
  • MOLECULE TYPE DNA
  • SEQUENCE DESCRIPTION SEQ ID NO: 11:
  • GTC GCC ATG GCT AAG AGA TTC GTT AAC CAA CAC TTG TGC GGT TCT CAC 256 Val Ala Met Ala Lys Arg Phe Val Asn Gln His Leu Cys Gly Ser His
  • GTC GCC ATG GCT AAG AGA TTC GTT ACT CAA CAC TTG TGC GGT TCT CAC 256 Val Ala Met Ala Lys Arg Phe Val Thr Gln His Leu Cys Gly Ser His
  • GTC GCC ATG GCT AAG AGA TTC GTT ACT CAA CAC TTG TGC GGT TCT CAC 256 Val Ala Met Ala Lys Arg Phe Val Thr Gln His Leu Cys Gly Ser His

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/DK1994/000347 1993-09-17 1994-09-16 Acylated insulin WO1995007931A1 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
JP7508923A JP3014764B2 (ja) 1993-09-17 1994-09-16 アシル化インスリン
RO96-00583A RO112873B1 (ro) 1993-09-17 1994-09-16 Derivati de insulina
PL94313444A PL178466B1 (pl) 1993-09-17 1994-09-16 Pochodna insuliny i kompozycja farmaceutyczna do leczenia cukrzycy
DE69428134T DE69428134T2 (de) 1993-09-17 1994-09-16 Acyliertes insulin
AU76520/94A AU682061B2 (en) 1993-09-17 1994-09-16 Acylated insulin
NZ273285A NZ273285A (en) 1993-09-17 1994-09-16 Insulin derivatives and compositions thereof
SI9430396T SI0792290T1 (en) 1993-09-17 1994-09-16 Acylated insulin
DK94926816T DK0792290T3 (da) 1993-09-17 1994-09-16 Acyleret insulin
KR1019960701400A KR100310122B1 (ko) 1993-09-17 1994-09-16 아실화된인슐린
EP94926816A EP0792290B1 (en) 1993-09-17 1994-09-16 Acylated insulin
BR9407508A BR9407508A (pt) 1993-09-17 1994-09-16 Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento
SK324-96A SK282495B6 (sk) 1993-09-17 1994-09-16 Acylovaný inzulínový derivát a farmaceutický prostriedok, ktorý ho obsahuje
UA96030967A UA45321C2 (uk) 1993-09-17 1994-09-16 Похідне інсуліну, фармацевтична композиція для лікування діабету та спосіб лікування діабету
AT94926816T ATE204882T1 (de) 1993-09-17 1994-09-16 Acyliertes insulin
DE122004000035C DE122004000035I2 (de) 1993-09-17 1994-09-16 Acyliertes insulin
HU9600676A HU217684B (hu) 1993-09-17 1994-09-16 Acilezett inzulinszármazékok és azokat tartalmazó gyógyszerkészítmények és előállításuk
CA002171424A CA2171424C (en) 1993-09-17 1994-09-16 Acylated insulin
US08/400,256 US5750497A (en) 1993-09-17 1995-03-08 Acylated insulin
BG100420A BG61611B1 (bg) 1993-09-17 1996-03-13 Ацилиран инсулин
FI961220A FI117055B (fi) 1993-09-17 1996-03-15 Menetelmä asyloidun insuliinin valmistamiseksi
NO19961070A NO316944B1 (no) 1993-09-17 1996-03-15 Humaninsulinderivater og farmasoytiske preparater for behandling av diabetes
FR04C0020C FR04C0020I2 (fr) 1993-09-17 2004-09-06 Insuline acylee
LU91101C LU91101I2 (en) 1993-09-17 2004-09-08 Insuline acylee
NL300160C NL300160I2 (nl) 1993-09-17 2004-09-24 Geacyleerde insuline.
NO2004006C NO2004006I1 (no) 1993-09-17 2004-09-27 Insulin detemir
US11/169,100 US20060030518A1 (en) 1993-09-17 2005-06-28 Acylated insulin
NO2017041C NO2017041I2 (no) 1993-09-17 2017-08-01 Insulin detemir

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK104493A DK104493D0 (da) 1993-09-17 1993-09-17 Hidtil ukendte peptider
DK1044/93 1993-09-17
US19082994A 1994-02-02 1994-02-02
US08/190,829 1994-02-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/400,256 Continuation-In-Part US5750497A (en) 1993-09-17 1995-03-08 Acylated insulin

Publications (1)

Publication Number Publication Date
WO1995007931A1 true WO1995007931A1 (en) 1995-03-23

Family

ID=26065125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1994/000347 WO1995007931A1 (en) 1993-09-17 1994-09-16 Acylated insulin

Country Status (30)

Country Link
US (1) US5750497A (en, 2012)
EP (2) EP1132404A3 (en, 2012)
JP (3) JP3014764B2 (en, 2012)
KR (1) KR100310122B1 (en, 2012)
CN (1) CN1056618C (en, 2012)
AT (1) ATE204882T1 (en, 2012)
AU (2) AU682061B2 (en, 2012)
BG (1) BG61611B1 (en, 2012)
BR (1) BR9407508A (en, 2012)
CA (1) CA2171424C (en, 2012)
CZ (1) CZ287945B6 (en, 2012)
DE (2) DE69428134T2 (en, 2012)
DK (1) DK0792290T3 (en, 2012)
ES (1) ES2163451T3 (en, 2012)
FI (1) FI117055B (en, 2012)
FR (1) FR04C0020I2 (en, 2012)
HU (1) HU217684B (en, 2012)
IL (1) IL110977A (en, 2012)
LU (1) LU91101I2 (en, 2012)
NL (1) NL300160I2 (en, 2012)
NO (3) NO316944B1 (en, 2012)
NZ (1) NZ273285A (en, 2012)
PL (1) PL178466B1 (en, 2012)
PT (1) PT792290E (en, 2012)
RO (1) RO112873B1 (en, 2012)
RU (1) RU2164520C2 (en, 2012)
SI (1) SI0792290T1 (en, 2012)
SK (1) SK282495B6 (en, 2012)
UA (1) UA45321C2 (en, 2012)
WO (1) WO1995007931A1 (en, 2012)

Cited By (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012505A1 (de) * 1994-10-21 1996-05-02 Basf Aktiengesellschaft Konjugate aus einem poly- oder oligopeptid und einer niedermolekularen lipophilen verbindung
WO1996029344A1 (en) * 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
WO1997003089A3 (en) * 1995-07-08 1997-03-13 Univ Leicester Method for the preparation of insulin by cleavage of a fusion protein and fusion proteins containing insulin a and b chains
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
WO1997031022A1 (en) * 1996-02-21 1997-08-28 Novo Nordisk A/S Insulin derivatives and their use
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
WO1998002460A1 (en) * 1996-07-11 1998-01-22 Novo Nordisk A/S Selective acylation method
US5854208A (en) * 1993-08-13 1998-12-29 Deutsches Wollforschungsinstitut Hepatoselective pharmaceutical actives
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
WO1999032116A1 (en) * 1997-12-23 1999-07-01 Eli Lilly And Company Insoluble compositions for controlling blood glucose
WO1999043361A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999065941A1 (en) * 1998-06-12 1999-12-23 Kings College London Insulin analogue
WO1999064598A3 (de) * 1998-06-06 2000-03-16 Aventis Pharma Gmbh Neue insulinanaloga mit erhöhter zinkbindung
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6051551A (en) * 1997-10-31 2000-04-18 Eli Lilly And Company Method for administering acylated insulin
RU2152399C2 (ru) * 1994-06-16 2000-07-10 Эли Лилли Энд Компани Комплекс, содержащий аналог человеческого инсулина, и фармацевтическая композиция на его основе
RU2156257C2 (ru) * 1994-06-16 2000-09-20 Эли Лилли Энд Компани Способ получения стабильного кристаллического аналога цинк-инсулина
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268335B1 (en) 1997-10-24 2001-07-31 Eli Lilly And Company Insoluble insulin compositions
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
WO2002004515A1 (en) * 2000-07-10 2002-01-17 Btg International Limited Insulin derivatives and synthesis thereof
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
EP0911035A3 (en) * 1997-10-24 2002-08-21 Eli Lilly And Company Insoluble insulin compositions
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6653492B2 (en) 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
RU2218349C2 (ru) * 1997-10-24 2003-12-10 Ново Нордиск А/С Агрегаты производных инсулина человека
EP1396272A1 (en) * 1997-12-23 2004-03-10 Eli Lilly & Company Insoluble Insulin Compositions for Controlling Blood Glucose
WO2004029077A3 (en) * 2002-09-25 2004-05-13 Novo Nordisk As Method for producing acylated peptides
WO2004085472A1 (en) * 2003-03-27 2004-10-07 Novo Nordisk A/S Method for making human insulin precursors and human insulin
WO2004096266A1 (en) * 2003-05-02 2004-11-11 Novo Nordisk A/S Improved physical stability of insulin formulations
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
WO2005012347A3 (en) * 2003-08-05 2005-04-14 Novo Nordisk As Novel insulin derivatives
WO2005047508A1 (en) 2003-11-14 2005-05-26 Novo Nordisk A/S Processes for making acylated insulin
WO2006008238A1 (en) * 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
WO2006082205A1 (en) * 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
EP1698636A1 (en) * 2001-05-02 2006-09-06 Novo Nordisk A/S Preparation of derivatized peptides from bile acids
WO2006125765A3 (en) * 2005-05-26 2007-02-15 Novo Nordisk As Acylated insulin with high purity
US7179788B2 (en) 2001-10-19 2007-02-20 Eli Lilly And Company Biphasic mixtures of GLP-1 and insulin
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7238663B2 (en) 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
WO2007074133A2 (en) 2005-12-28 2007-07-05 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
WO2007084460A2 (en) 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
WO2007096431A1 (en) * 2006-02-27 2007-08-30 Novo Nordisk A/S Insulin derivatives
US7268112B2 (en) 2000-03-24 2007-09-11 Genetech, Inc. Use of insulin for the treatment of cartilaginous disorders
WO2007104737A1 (en) * 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
WO2007128815A1 (en) 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
WO2007128817A3 (en) * 2006-05-09 2008-03-06 Novo Nordisk As Insulin derivative
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
WO2009021955A1 (en) 2007-08-13 2009-02-19 Novo Nordisk A/S Rapid acting insulin analogues
EP2033662A1 (en) 2004-01-21 2009-03-11 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
EP2058330A1 (en) * 2007-11-08 2009-05-13 Novo Nordisk A/S Insulin derivative
WO2009060071A1 (en) * 2007-11-08 2009-05-14 Novo Nordisk A/S Insulin derivative
JP2009235075A (ja) * 1996-06-20 2009-10-15 Novo Nordisk As ＮａＣｌ含有インスリン製剤
EP2264066A2 (en) 2003-08-05 2010-12-22 Novo Nordisk A/S Novel insulin derivatives
CN102504022A (zh) * 2011-11-30 2012-06-20 苏州元基生物技术有限公司 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
US8206735B2 (en) 2006-07-11 2012-06-26 Foresee Pharmaceuticals, Llc Pharmaceutical compositions for sustained release delivery of peptides
EP2514406A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
EP2514407A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
EP2597103A1 (en) 2007-11-16 2013-05-29 Novo Nordisk A/S Pharmaceutical compositions containing insulin and an insulinotropic peptide
WO2013164375A1 (en) 2012-05-01 2013-11-07 Novo Nordisk A/S Pharmaceutical composition
US8710001B2 (en) 2006-07-31 2014-04-29 Novo Nordisk A/S PEGylated, extended insulins
US9018161B2 (en) 2006-09-22 2015-04-28 Novo Nordisk A/S Protease resistant insulin analogues
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
EP2784085A4 (en) * 2011-12-15 2015-07-08 Shanghai Hengrui Pharm Co Ltd HUMAN INSULIN ANALOG AND ACYLATED DERIVATIVITY THEREOF
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
US9492507B2 (en) 2010-04-02 2016-11-15 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US9688737B2 (en) 2008-03-18 2017-06-27 Novo Nordisk A/S Protease stabilized acylated insulin analogues
US9896496B2 (en) 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
US10040839B2 (en) 2014-02-28 2018-08-07 Novo Nordisk A/S Insulin derivatives and the medical uses hereof
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US10265385B2 (en) 2016-12-16 2019-04-23 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2019154311A1 (zh) 2018-02-09 2019-08-15 江苏恒瑞医药股份有限公司 一种密码子优化的人胰岛素类似物前体基因和信号肽基因
WO2019223752A1 (zh) 2018-05-24 2019-11-28 江苏恒瑞医药股份有限公司 一种重组人胰岛素或其类似物的前体的制备方法
US10596229B2 (en) 2010-10-27 2020-03-24 Novo Nordisk A/S Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
WO2021022149A1 (en) 2019-07-31 2021-02-04 Eli Lilly And Company Insulin analogs and methods of using the same
WO2021136302A1 (zh) 2019-12-30 2021-07-08 甘李药业股份有限公司 胰岛素衍生物
US11098102B2 (en) 2018-12-11 2021-08-24 Sanofi Insulin conjugates
EP3689914A4 (en) * 2017-09-29 2021-08-25 Hanmi Pharm. Co., Ltd. ENHANCED PERSISTENT PROTEIN CONJUGATE
US11318191B2 (en) 2020-02-18 2022-05-03 Novo Nordisk A/S GLP-1 compositions and uses thereof
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023143458A1 (zh) 2022-01-28 2023-08-03 甘李药业股份有限公司 酰化胰岛素
US11752198B2 (en) 2017-08-24 2023-09-12 Novo Nordisk A/S GLP-1 compositions and uses thereof
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010041786A1 (en) * 1995-06-07 2001-11-15 Mark L. Brader Stabilized acylated insulin formulations
ES2218622T3 (es) * 1996-07-26 2004-11-16 Aventis Pharma Deutschland Gmbh Derivados de insulina con actividad de union al zinc incrementada.
US20020025933A1 (en) * 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
KR20000076419A (ko) * 1997-03-20 2000-12-26 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 폐 투여용 무아연 인슐린 결정 조성물
EP1044016B1 (en) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
WO2001085256A2 (en) * 2000-05-05 2001-11-15 Novo Nordisk A/S Critical illness neuropathy
CN1406131A (zh) * 2000-12-25 2003-03-26 株式会社资生堂 活化交感神经的香料组合物
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
RU2299743C2 (ru) * 2001-07-05 2007-05-27 Транслэйшнл Рисерч Лтд. Композиции инсулина для носового введения
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
DE60234198D1 (de) 2001-09-07 2009-12-10 Biocon Ltd Verfahren zur synthese von insulinpolypeptid-oligomer-konjugaten und proinsulinpolypeptid-oligomer-konjugaten und verfahren zu deren synthese
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
EP1444219A1 (en) 2001-10-12 2004-08-11 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
DE60236014D1 (de) 2001-11-19 2010-05-27 Novo Nordisk As Verfahren zur herstellung von insulinverbindungen
GB0206792D0 (en) 2002-03-22 2002-05-01 Leuven K U Res & Dev Normoglycemia
DE60335797D1 (de) * 2002-05-07 2011-03-03 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
AU2003236521A1 (en) 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
ATE467616T1 (de) 2003-04-11 2010-05-15 High Point Pharmaceuticals Llc Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
KR20060029154A (ko) 2003-06-27 2006-04-04 노보 노르디스크 에이/에스 의학적 액체 조성물을 위한 고 차습 용기
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
WO2005054291A1 (en) 2003-12-03 2005-06-16 Novo Nordisk A/S Single-chain insulin
JP2007515235A (ja) 2003-12-22 2007-06-14 ノボ・ノルデイスク・エー／エス 医薬液を保存するための、透明で、可撓性且つ不浸透性のプラスチック製容器
CA2558835C (en) * 2004-03-12 2011-06-28 Biodel, Inc. Rapid acting drug delivery compositions
DK1773878T3 (en) 2004-07-19 2015-05-11 Biocon Ltd Insulin-oligomerkonjugater, formulations and uses thereof
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
JP2008542235A (ja) * 2005-05-25 2008-11-27 ノボ・ノルデイスク・エー／エス 安定化ポリペプチド製剤
US8097584B2 (en) 2005-05-25 2012-01-17 Novo Nordisk A/S Stabilized formulations of insulin that comprise ethylenediamine
CA2614116A1 (en) 2005-07-04 2007-01-11 Novo Nordisk A/S Novel medicaments
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
ATE513921T1 (de) 2005-08-16 2011-07-15 Novo Nordisk As Verfahren zur herstellung reifer insulinpolypeptide
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7863329B2 (en) 2005-11-17 2011-01-04 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
WO2007104786A1 (en) 2006-03-15 2007-09-20 Novo Nordisk A/S Mixtures of amylin and insulin
CA2645581A1 (en) 2006-03-28 2007-10-04 High Point Pharmaceuticals, Llc Benzothiazoles having histamine h3 receptor activity
CN101432262B (zh) 2006-04-24 2011-06-01 伊莱利利公司 作为11-β-羟类固醇脱氢酶1的抑制剂的环己基取代的吡咯烷酮类
CN101437849B (zh) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 胰岛素衍生物
US7714025B2 (en) * 2006-05-10 2010-05-11 Arizona Biomedical Research Commission Modified chalcone compounds as antimitotic agents
DK2079732T3 (da) 2006-05-29 2012-01-23 High Point Pharmaceuticals Llc 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazin, dets salte og solvater og dets anvendelse som histamin H3-receptorantagonister
US8518668B2 (en) 2006-09-27 2013-08-27 Novo Nordisk A/S Method for making maturated insulin polypeptides in a fungal cell
WO2008049711A1 (en) * 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
AU2008313248B2 (en) * 2007-10-16 2012-04-26 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
US20090175840A1 (en) * 2008-01-04 2009-07-09 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
MX2011001408A (es) 2008-08-07 2011-05-02 Biocon Ltd Proceso para la preparacion de compuestos de insulina.
EA020496B1 (ru) 2008-11-21 2014-11-28 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Производное адамантилбензамида, фармацевтическая композиция, включающая его, и его применение
EP2391217A4 (en) 2009-01-28 2015-05-20 Smartcells Inc SYNTHETIC CONJUGATES AND USES THEREOF
PE20120583A1 (es) * 2009-01-28 2012-05-19 Smartcells Inc Sistemas basados en conjugados para entrega farmacologica controlada
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
JP2012520879A (ja) 2009-03-20 2012-09-10 スマートセルズ・インコーポレイテツド 末端官能基化コンジュゲートおよびその用途
WO2010140148A1 (en) 2009-06-01 2010-12-09 Yeda Research And Development Co . Ltd Prodrugs containing albumin binding probe
BR112012012945A2 (pt) 2009-11-25 2020-12-29 Arisgen Sa Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
EP2460527A1 (en) 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
UY33326A (es) 2010-04-14 2011-12-01 Sanofi Aventis Conjugados de insulina-sirna
CN102883743A (zh) * 2010-05-10 2013-01-16 诺沃—诺迪斯克有限公司 用于制备胰岛素-锌复合物的方法
JP2013540771A (ja) * 2010-10-15 2013-11-07 ノヴォ ノルディスク アー／エス 新規ｎ末端修飾インスリン誘導体
SG191298A1 (en) 2010-12-22 2013-07-31 Baxter Int Materials and methods for conjugating a water soluble fatty acid derivative to a protein
PH12013501495A1 (en) 2011-01-20 2013-09-16 Zealand Pharma As Combination of acylated glucagon analogues with insulin analogues
EP2670368A4 (en) 2011-02-03 2015-04-15 Pharmedica Ltd NEW ORAL DISSOLUTION FILMS FOR INSULIN DELIVERY FOR THE TREATMENT OF DIABETES
WO2012140647A2 (en) 2011-04-11 2012-10-18 Yeda Research And Development Co. Ltd Albumin binding probes and drug conjugates thereof
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
CA2924109A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CA2933701C (en) 2013-12-18 2022-05-31 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
US9656017B2 (en) 2014-06-20 2017-05-23 Howard E. Greene Infusion delivery devices and methods
CN107921098A (zh) 2015-06-17 2018-04-17 加州生物医学研究所 修饰的治疗剂及其组合物
TW201717998A (zh) 2015-08-25 2017-06-01 諾佛 儂迪克股份有限公司 新穎胰島素衍生物及其醫學用途
US10815287B2 (en) 2016-08-02 2020-10-27 Jiangsu Hengrui Medicine Co., Ltd. Acylated derivative of human insulin or analogue thereof
CN110381976A (zh) 2016-12-05 2019-10-25 努里塔斯有限公司 包括肽wkdeagkplvk的组合物
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
EP3740212A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
CN111909255A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 胰岛素衍生物及其制备方法
DK4073097T3 (da) 2019-12-11 2024-08-19 Novo Nordisk As Nye insulinanaloger og anvendelser heraf
MX2022008139A (es) 2019-12-30 2022-10-03 Gan & Lee Pharmaceuticals Co Ltd Compuestos de glp-1 de acción prolongada.
JP2023520049A (ja) 2020-03-31 2023-05-15 プロトマー・テクノロジーズ・インコーポレイテッド 隣接ジオールに対する選択的応答性のためのコンジュゲート
JP2024500284A (ja) 2020-11-19 2024-01-09 プロトマー・テクノロジーズ・インコーポレイテッド 芳香族ホウ素含有化合物及びインスリン類似体
KR20240032010A (ko) 2021-06-09 2024-03-08 더 스크립스 리서치 인스티튜트 장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법
WO2024051787A1 (zh) * 2022-09-09 2024-03-14 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3823125A (en) * 1969-10-14 1974-07-09 American Home Prod N-aminoacyl-substituted insulins
US3868356A (en) * 1971-01-28 1975-02-25 Nat Res Dev N-Acylated, O-substituted insulin derivatives
DE2209835B2 (de) * 1972-03-01 1976-04-29 Bayer Ag, 5090 Leverkusen Insulinderivate, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel
EP0127535A2 (en) * 1983-05-23 1984-12-05 Hadassah Medical Organization Pharmaceutical compositions containing insulin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
DK319780A (da) * 1980-07-24 1982-01-25 Forenede Bryggerier As Fremgangsmaade til enzymatisk udskiftning af b-30 aminosyren i insuliner
NL8201650A (nl) * 1982-04-21 1983-11-16 Akzo Nv Semisynthetische bereiding van humane insuline.
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
JPH01254699A (ja) * 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DK45590D0 (en, 2012) * 1990-02-21 1990-02-21 Novo Nordisk As
DK155690D0 (da) * 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
AU8091091A (en) * 1990-07-26 1992-02-18 University Of Iowa Research Foundation, The Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
US5336782A (en) * 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3823125A (en) * 1969-10-14 1974-07-09 American Home Prod N-aminoacyl-substituted insulins
US3868356A (en) * 1971-01-28 1975-02-25 Nat Res Dev N-Acylated, O-substituted insulin derivatives
DE2209835B2 (de) * 1972-03-01 1976-04-29 Bayer Ag, 5090 Leverkusen Insulinderivate, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel
EP0127535A2 (en) * 1983-05-23 1984-12-05 Hadassah Medical Organization Pharmaceutical compositions containing insulin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN, Vol. 14, No. 7, C-673; & JP,A,01 254 699 (KODAMA K.K.), 11 October 1989. *

Cited By (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854208A (en) * 1993-08-13 1998-12-29 Deutsches Wollforschungsinstitut Hepatoselective pharmaceutical actives
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6063761A (en) * 1993-08-13 2000-05-16 Kings College London Hepatoselective pharmaceutical actives
EP1234586A3 (en) * 1993-08-13 2003-04-09 BTG International Limited Hepatoselective pharmaceutical actives
USRE39055E1 (en) * 1993-08-13 2006-04-04 Btg International Limited Hepatoselective pharmaceutical actives
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
RU2152399C2 (ru) * 1994-06-16 2000-07-10 Эли Лилли Энд Компани Комплекс, содержащий аналог человеческого инсулина, и фармацевтическая композиция на его основе
RU2156257C2 (ru) * 1994-06-16 2000-09-20 Эли Лилли Энд Компани Способ получения стабильного кристаллического аналога цинк-инсулина
WO1996012505A1 (de) * 1994-10-21 1996-05-02 Basf Aktiengesellschaft Konjugate aus einem poly- oder oligopeptid und einer niedermolekularen lipophilen verbindung
EP0712861A3 (en) * 1994-11-17 1998-03-11 Eli Lilly And Company Acylated insulin analogs
EP0712862A3 (en) * 1994-11-17 1998-03-04 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5922675A (en) * 1994-11-17 1999-07-13 Eli Lilly And Company Acylated Insulin Analogs
USRE37971E1 (en) 1994-11-17 2003-01-28 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
EP1227107A1 (en) * 1994-11-17 2002-07-31 Eli Lilly And Company Selective acylation of E-amino groups
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6620780B2 (en) 1995-03-17 2003-09-16 Novo Nordisk A/S Insulin derivatives
US7229964B2 (en) 1995-03-17 2007-06-12 Novo Nordisk A/S Insulin derivatives
WO1996029344A1 (en) * 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
WO1997003089A3 (en) * 1995-07-08 1997-03-13 Univ Leicester Method for the preparation of insulin by cleavage of a fusion protein and fusion proteins containing insulin a and b chains
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
WO1997031022A1 (en) * 1996-02-21 1997-08-28 Novo Nordisk A/S Insulin derivatives and their use
JP2009235075A (ja) * 1996-06-20 2009-10-15 Novo Nordisk As ＮａＣｌ含有インスリン製剤
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
WO1998002460A1 (en) * 1996-07-11 1998-01-22 Novo Nordisk A/S Selective acylation method
US8097698B2 (en) 1996-08-30 2012-01-17 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6818738B2 (en) * 1997-03-20 2004-11-16 Novo Nordisk A/S Pulmonary insulin crystals
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
EP1039920A4 (en) * 1997-10-24 2003-05-28 Lilly Co Eli INSULIN ANALOGS ACYLATED BY FATTY ACID
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
EP0911035A3 (en) * 1997-10-24 2002-08-21 Eli Lilly And Company Insoluble insulin compositions
US6465426B2 (en) 1997-10-24 2002-10-15 Eli Lilly And Company Insoluble insulin compositions
US6268335B1 (en) 1997-10-24 2001-07-31 Eli Lilly And Company Insoluble insulin compositions
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
RU2218349C2 (ru) * 1997-10-24 2003-12-10 Ново Нордиск А/С Агрегаты производных инсулина человека
EP0919242A3 (en) * 1997-10-31 2003-01-02 Eli Lilly And Company Method for administering acylated insulin
US6051551A (en) * 1997-10-31 2000-04-18 Eli Lilly And Company Method for administering acylated insulin
EP0925792A3 (en) * 1997-12-23 2001-09-12 Eli Lilly And Company Insoluble compositions for controlling blood glucose
EA003394B1 (ru) * 1997-12-23 2003-04-24 Эли Лилли Энд Компани Нерастворимые инсулинсодержащие композиции, способы их получения, суспензионный препарат, способ лечения диабета и гипергликемии
EP1396272A1 (en) * 1997-12-23 2004-03-10 Eli Lilly & Company Insoluble Insulin Compositions for Controlling Blood Glucose
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
WO1999032116A1 (en) * 1997-12-23 1999-07-01 Eli Lilly And Company Insoluble compositions for controlling blood glucose
WO1999043361A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999064598A3 (de) * 1998-06-06 2000-03-16 Aventis Pharma Gmbh Neue insulinanaloga mit erhöhter zinkbindung
CZ301377B6 (cs) * 1998-06-06 2010-02-03 Sanofi - Aventis Deutschland GmbH Analogy inzulínu, zpusob jejich prípravy a farmaceutické prípravky obsahující tyto analogy
WO1999065941A1 (en) * 1998-06-12 1999-12-23 Kings College London Insulin analogue
US7268112B2 (en) 2000-03-24 2007-09-11 Genetech, Inc. Use of insulin for the treatment of cartilaginous disorders
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
WO2002004515A1 (en) * 2000-07-10 2002-01-17 Btg International Limited Insulin derivatives and synthesis thereof
EP1698636A1 (en) * 2001-05-02 2006-09-06 Novo Nordisk A/S Preparation of derivatized peptides from bile acids
US6653492B2 (en) 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
US7238663B2 (en) 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
US7179788B2 (en) 2001-10-19 2007-02-20 Eli Lilly And Company Biphasic mixtures of GLP-1 and insulin
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
WO2004029077A3 (en) * 2002-09-25 2004-05-13 Novo Nordisk As Method for producing acylated peptides
US9562910B2 (en) 2002-09-25 2017-02-07 Novo Nordisk A/S Method for producing acylated peptides
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
WO2004085472A1 (en) * 2003-03-27 2004-10-07 Novo Nordisk A/S Method for making human insulin precursors and human insulin
WO2004096266A1 (en) * 2003-05-02 2004-11-11 Novo Nordisk A/S Improved physical stability of insulin formulations
EP2107069A3 (en) * 2003-08-05 2009-11-25 Novo Nordisk A/S Novel insulin derivatives
EP2264066A3 (en) * 2003-08-05 2011-07-27 Novo Nordisk A/S Novel insulin derivatives
US8828923B2 (en) 2003-08-05 2014-09-09 Novo Nordisk A/S Insulin derivatives
US7615532B2 (en) 2003-08-05 2009-11-10 Novo Nordisk A/S Insulin derivatives
EP2287184A3 (en) * 2003-08-05 2011-08-10 Novo Nordisk A/S Novel insulin derivatives
EP2264065A3 (en) * 2003-08-05 2011-07-27 Novo Nordisk A/S Novel Insulin Derivatives
NO340925B1 (no) * 2003-08-05 2017-07-17 Novo Nordisk As Nye insulinderivater
AU2004261353B2 (en) * 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
EP2287184A2 (en) 2003-08-05 2011-02-23 Novo Nordisk A/S Novel insulin derivatives
WO2005012347A3 (en) * 2003-08-05 2005-04-14 Novo Nordisk As Novel insulin derivatives
EP2275439A2 (en) 2003-08-05 2011-01-19 Novo Nordisk A/S Novel insulin derivatives
EP2264065A2 (en) 2003-08-05 2010-12-22 Novo Nordisk A/S Novel Insulin Derivatives
AU2010200497B2 (en) * 2003-08-05 2014-10-23 Novo Nordisk A/S Novel insulin derivatives
EP2107069A2 (en) 2003-08-05 2009-10-07 Novo Nordisk A/S Novel insulin derivatives
EP2264066A2 (en) 2003-08-05 2010-12-22 Novo Nordisk A/S Novel insulin derivatives
WO2005047508A1 (en) 2003-11-14 2005-05-26 Novo Nordisk A/S Processes for making acylated insulin
EP2033662A1 (en) 2004-01-21 2009-03-11 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
EP2368579A1 (en) 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
WO2006008238A1 (en) * 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
US8067362B2 (en) 2005-02-02 2011-11-29 Novo Nordisk As Insulin derivatives
EP2256130A1 (en) 2005-02-02 2010-12-01 Novo Nordisk A/S Novel insulin derivatives
WO2006082205A1 (en) * 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
USRE46170E1 (en) 2005-02-02 2016-10-04 Novo Nordisk A/S Insulin derivatives
US8476228B2 (en) 2005-02-02 2013-07-02 Novo Nordisk A/S Insulin derivatives
EP2292653A1 (en) 2005-02-02 2011-03-09 Novo Nordisk A/S Novel insulin derivatives
JP2008528658A (ja) * 2005-02-02 2008-07-31 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
US8859493B2 (en) 2005-02-02 2014-10-14 Novo Nordisk A/S Insulin derivatives
WO2006125765A3 (en) * 2005-05-26 2007-02-15 Novo Nordisk As Acylated insulin with high purity
WO2007074133A2 (en) 2005-12-28 2007-07-05 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
US11167035B2 (en) 2005-12-28 2021-11-09 Novo Nordisk A/S Insulin compositions and method of making a composition
EP2505593A1 (en) 2005-12-28 2012-10-03 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
WO2007084460A2 (en) 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
EP2256129A1 (en) 2006-02-27 2010-12-01 Novo Nordisk A/S Insulin derivatives
WO2007096431A1 (en) * 2006-02-27 2007-08-30 Novo Nordisk A/S Insulin derivatives
US8722620B2 (en) 2006-02-27 2014-05-13 Novo Nordisk A/S Insulin derivatives
WO2007104737A1 (en) * 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
KR101441444B1 (ko) 2006-05-09 2014-09-18 노보 노르디스크 에이/에스 인슐린 유도체
WO2007128817A3 (en) * 2006-05-09 2008-03-06 Novo Nordisk As Insulin derivative
WO2007128815A1 (en) 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative
US8933021B2 (en) 2006-05-09 2015-01-13 Novo Nordisk A/S Insulin derivative
US8796205B2 (en) 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
EP2386572A1 (en) 2006-05-09 2011-11-16 Novo Nordisk A/S Insulin derivative
RU2451029C2 (ru) * 2006-05-09 2012-05-20 Ново Нордиск А/С Производное инсулина
US8840915B2 (en) 2006-07-11 2014-09-23 Foresec Pharmaceuticals, LLC Pharmaceutical compositions for sustained release delivery of peptides
US8206735B2 (en) 2006-07-11 2012-06-26 Foresee Pharmaceuticals, Llc Pharmaceutical compositions for sustained release delivery of peptides
US8710001B2 (en) 2006-07-31 2014-04-29 Novo Nordisk A/S PEGylated, extended insulins
US9018161B2 (en) 2006-09-22 2015-04-28 Novo Nordisk A/S Protease resistant insulin analogues
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
EP2514406A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
EP2514407A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
WO2009021955A1 (en) 2007-08-13 2009-02-19 Novo Nordisk A/S Rapid acting insulin analogues
EP2058330A1 (en) * 2007-11-08 2009-05-13 Novo Nordisk A/S Insulin derivative
US8710000B2 (en) 2007-11-08 2014-04-29 Novo Nordisk A/S Insulin derivative
WO2009060071A1 (en) * 2007-11-08 2009-05-14 Novo Nordisk A/S Insulin derivative
EP2597103A1 (en) 2007-11-16 2013-05-29 Novo Nordisk A/S Pharmaceutical compositions containing insulin and an insulinotropic peptide
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
US10259856B2 (en) 2008-03-18 2019-04-16 Novo Nordisk A/S Protease stabilized acylated insulin analogues
US9688737B2 (en) 2008-03-18 2017-06-27 Novo Nordisk A/S Protease stabilized acylated insulin analogues
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US10744187B2 (en) 2010-04-02 2020-08-18 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
US9492507B2 (en) 2010-04-02 2016-11-15 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
US10596229B2 (en) 2010-10-27 2020-03-24 Novo Nordisk A/S Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
CN102504022A (zh) * 2011-11-30 2012-06-20 苏州元基生物技术有限公司 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
EP2784085A4 (en) * 2011-12-15 2015-07-08 Shanghai Hengrui Pharm Co Ltd HUMAN INSULIN ANALOG AND ACYLATED DERIVATIVITY THEREOF
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
US9884094B2 (en) 2012-05-01 2018-02-06 Novo Nordisk A/S Method of treating diabetes mellitus
WO2013164375A1 (en) 2012-05-01 2013-11-07 Novo Nordisk A/S Pharmaceutical composition
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US9896496B2 (en) 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
US10040839B2 (en) 2014-02-28 2018-08-07 Novo Nordisk A/S Insulin derivatives and the medical uses hereof
US10596231B2 (en) 2016-12-16 2020-03-24 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US10265385B2 (en) 2016-12-16 2019-04-23 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US11752198B2 (en) 2017-08-24 2023-09-12 Novo Nordisk A/S GLP-1 compositions and uses thereof
US12214017B2 (en) 2017-08-24 2025-02-04 Novo Nordisk A/S GLP-1 compositions and uses thereof
EP3689914A4 (en) * 2017-09-29 2021-08-25 Hanmi Pharm. Co., Ltd. ENHANCED PERSISTENT PROTEIN CONJUGATE
WO2019154311A1 (zh) 2018-02-09 2019-08-15 江苏恒瑞医药股份有限公司 一种密码子优化的人胰岛素类似物前体基因和信号肽基因
WO2019223752A1 (zh) 2018-05-24 2019-11-28 江苏恒瑞医药股份有限公司 一种重组人胰岛素或其类似物的前体的制备方法
US12226458B2 (en) 2018-06-26 2025-02-18 Novo Nordisk A/S System for providing an up-to-date and long-acting or ultra-long-acting insulin dose guidance recommendation to treat diabetes mellitus
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US11098102B2 (en) 2018-12-11 2021-08-24 Sanofi Insulin conjugates
US12195510B2 (en) 2018-12-11 2025-01-14 Sanofi Insulin conjugates
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
WO2021022149A1 (en) 2019-07-31 2021-02-04 Eli Lilly And Company Insulin analogs and methods of using the same
WO2021136296A1 (zh) 2019-12-30 2021-07-08 甘李药业股份有限公司 胰岛素衍生物
WO2021136293A1 (zh) 2019-12-30 2021-07-08 甘李药业股份有限公司 胰岛素衍生物
WO2021136302A1 (zh) 2019-12-30 2021-07-08 甘李药业股份有限公司 胰岛素衍生物
US11318191B2 (en) 2020-02-18 2022-05-03 Novo Nordisk A/S GLP-1 compositions and uses thereof
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023143458A1 (zh) 2022-01-28 2023-08-03 甘李药业股份有限公司 酰化胰岛素
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
WO2024003400A1 (en) 2022-07-01 2024-01-04 Adocia Compositions comprising a peptide or a protein and an acylated amino acid

Also Published As

Publication number Publication date
JP3014764B2 (ja) 2000-02-28
FR04C0020I2 (fr) 2005-05-27
NO2017041I1 (no) 2017-08-01
NL300160I2 (nl) 2005-07-01
CA2171424C (en) 2002-06-04
ES2163451T3 (es) 2002-02-01
SK282495B6 (sk) 2002-02-05
NO961070D0 (no) 1996-03-15
HU9600676D0 (en) 1996-05-28
HUT75991A (en) 1997-05-28
JP2002308899A (ja) 2002-10-23
IL110977A (en) 2000-06-29
PL313444A1 (en) 1996-07-08
DE69428134D1 (de) 2001-10-04
RO112873B1 (ro) 1998-01-30
JPH09502867A (ja) 1997-03-25
HU217684B (hu) 2000-03-28
LU91101I2 (en) 2004-11-08
CN1056618C (zh) 2000-09-20
EP0792290A1 (en) 1997-09-03
JP4060583B2 (ja) 2008-03-12
PL178466B1 (pl) 2000-05-31
DE122004000035I1 (de) 2005-02-24
NO316944B1 (no) 2004-07-05
US5750497A (en) 1998-05-12
AU4846197A (en) 1998-02-19
NO2004006I2 (en, 2012) 2008-02-04
EP0792290B1 (en) 2001-08-29
NO961070L (no) 1996-05-15
AU7652094A (en) 1995-04-03
EP1132404A3 (en) 2002-03-27
FR04C0020I1 (en, 2012) 2004-10-29
NO2004006I1 (no) 2004-10-11
DE122004000035I2 (de) 2009-08-06
CN1133598A (zh) 1996-10-16
KR100310122B1 (ko) 2002-04-24
CZ287945B6 (cs) 2001-03-14
NZ273285A (en) 1997-10-24
FI961220L (fi) 1996-05-14
DE69428134T2 (de) 2002-05-02
AU682061B2 (en) 1997-09-18
UA45321C2 (uk) 2002-04-15
IL110977A0 (en) 1994-11-28
CA2171424A1 (en) 1995-03-23
RU2164520C2 (ru) 2001-03-27
JP2000060556A (ja) 2000-02-29
FI961220A0 (fi) 1996-03-15
BG61611B1 (bg) 1998-01-30
PT792290E (pt) 2002-01-30
CZ78996A3 (en) 1996-10-16
JP3917333B2 (ja) 2007-05-23
EP1132404A2 (en) 2001-09-12
BR9407508A (pt) 1997-01-07
SK32496A3 (en) 1996-11-06
FI117055B (fi) 2006-05-31
KR960704925A (ko) 1996-10-09
BG100420A (bg) 1996-12-31
NO2017041I2 (no) 2018-11-19
NL300160I1 (nl) 2004-12-01
SI0792290T1 (en) 2001-12-31
DK0792290T3 (da) 2001-10-01
ATE204882T1 (de) 2001-09-15

Similar Documents

Publication Publication Date Title
EP0792290B1 (en) Acylated insulin
US6869930B1 (en) Acylated insulin
US6011007A (en) Acylated insulin
US6251856B1 (en) Insulin derivatives
EP0871665B1 (en) Insulin derivatives
AU745983B2 (en) Acylated insulin
MXPA97007056A (en) Insulated derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 94193852.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KE KG KP KR KZ LK LR LT LV MD MG MN MW NO NZ PL RO RU SD SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2171424

Country of ref document: CA

Ref document number: 32496

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1994926816

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 273285

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV1996-789

Country of ref document: CZ

Ref document number: 961220

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 96-00583

Country of ref document: RO

Ref document number: 1019960701400

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV1996-789

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1994926816

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1997 975365

Country of ref document: US

Date of ref document: 19971120

Kind code of ref document: A

WWG Wipo information: grant in national office

Ref document number: PV1996-789

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1994926816

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 961220

Country of ref document: FI